Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma-Reference-Cited by-同舟云学术

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

Published:2013-02 Issue:2 Volume:128 Page:221-228
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Tillmanns Todd D.,Lowe M. Patrick,Walker Mark S.,Stepanski Edward J.,Schwartzberg Lee S.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference38 articles.

1. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics;Goff;JAMA,2004

2. Cancer facts and figures 2011;American Cancer Society,2011

3. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet,2003

4. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J Clin Oncol,2006

5. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation;Muggia;J Clin Oncol,1997

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies;Clinical Cancer Research;2024-03-26

2. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer;In Vivo;2024

3. Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or -Allergic Metastatic Ovarian Cancer;TURK ONCOL DERG;2024

4. Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-05

5. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18